Compare BMHL & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | BNR |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | China |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 169.9M |
| IPO Year | 2024 | 2019 |
| Metric | BMHL | BNR |
|---|---|---|
| Price | $3.50 | $15.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 36.7K |
| Earning Date | 03-30-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.46 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $6.79 |
| 52 Week High | $6.35 | $41.72 |
| Indicator | BMHL | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 51.96 |
| Support Level | $3.20 | $8.91 |
| Resistance Level | $3.88 | $19.10 |
| Average True Range (ATR) | 0.52 | 1.46 |
| MACD | -0.13 | -0.42 |
| Stochastic Oscillator | 8.55 | 11.56 |
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.